The anti-obesity drugs market size is projected to reach US$ 177.27 billion by 2031 from US$ 15.85 billion in 2024. The market is expected to register a CAGR of 35.3% during 2025–2031. Precision medicine and personalized anti-obesity drug regimens are likely to bring in new market trends during the forecast period.
Anti-obesity Drugs Market Analysis
According to the World Health Organization (WHO), the global prevalence of obesity more than doubled between 1990 and 2022. In 2022, 2.5 billion adults aged 18 and older were overweight, with over 890 million classified as obese: this equates to 43% of adults (43% of men and 44% of women), up from 25% in 1990. Overweight prevalence varied by region, with rates as low as 31% in the WHO South-East Asia and African Regions and reaching up to 67% in the Region of the Americas. Reducing obesity rates could alleviate the economic burden associated with the disease. According to the World Obesity Atlas, the total costs related to obesity—including healthcare and economic productivity losses—are expected to exceed US$ 4 trillion by 2035, accounting for approximately 3% of global GDP from US$1.96 trillion in 2020. Thus, the rising obesity rates and awareness of associated health risks, such as diabetes, cardiovascular diseases, and certain types of cancer, fuel demand for anti-obesity drugs.
Anti-obesity Drugs Market Overview
The anti-obesity drugs market is expanding due to the mounting prevalence of obesity and increased awareness and demand for weight management solutions. Prominent players operating in the market are focusing on innovations and collaborative efforts for enhanced product availability and reach. However, the side effects and safety concerns hinder market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Anti-obesity Drugs Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Anti-obesity Drugs Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Anti-obesity Drugs Market Drivers and Opportunities
Increased Awareness and Demand for Weight Management Solutions Fuels Market Growth
In 2013, the American Medical Association officially recognized obesity as a disease with various biological factors that require multiple interventions for effective treatment and prevention. Obesity increases the risk of type 2 diabetes, cardiovascular disease, hypertension, and certain cancers. The heightened awareness among the public about these serious health risks has fuelled the demand for weight management solutions. This shift is reflected in public health initiatives and changes in consumer behavior, leading to a demand for weight loss services, products, and pharmaceuticals
Governments and pharmaceutical companies are increasing their efforts to educate the public about the dangers of obesity, particularly its links to diabetes, cardiovascular disease, and other chronic conditions. In March 2024, Eli Lilly and Company launched the next phase of its "Get Better" corporate branding campaign, focusing on obesity. Earlier that year, Lilly had introduced "Get Better" to emphasize its commitment to discovering and producing medicines that would help people achieve better health. As part of this ongoing campaign, Lilly released two films titled "Shame" and "Big Night." These films presented the company's perspective on obesity, highlighting the seriousness of the condition and the appropriate use of anti-obesity medications. In December 2022, Novo Nordisk launched the "Break the Partnership" campaign to educate individuals with diabetes, their caregivers, and healthcare professionals about the impact of weight on type 2 diabetes management. Officially launched by former cricketer Kapil Dev, the campaign encouraged discussions with clinicians about new treatment options that addressed blood glucose levels and weight. Over the following six months, the Novo Nordisk team engaged healthcare professionals through awareness events and scientific meetings in various cities.
The awareness of obesity drugs is surging worldwide. According to a cross-sectional study, ' Longitudinal Analysis of Obesity Drug Use and Public Awareness' published in JAMA Network in 2025, between July 2017 to February 2024, a total of 69,213,936 obesity management drug (OMD) prescriptions were dispensed in the US. From July 2017 to June 2018, the number of prescriptions increased from 0.76 to 0.80 million, while from March 2023 to February 2024, they rose from 1.29 to 1.51 million. The mean annual growth rate was 5.3%. In February 2024, OMD prescriptions reached 1.5 million, making up 0.41% of all prescriptions. The most prescribed medications included phentermine, semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound).
Expansion in Emerging Economies to Create Lucrative Opportunities in Market
According to a Lancet study published in July 2023, approximately 450 million adults in India are expected to be overweight or obese by 2050. In 2021, more than half of the world's adults who were classified as overweight or obese lived in India, with 180 million affected individuals; China, with 402 million; Brazil, with 88 million; Russia, with 71 million; Mexico, with 58 million; Indonesia, with 52 million; and Egypt, with 41 million.
According to the World Obesity Federation, Vietnam, Indonesia, and Bangladesh are experiencing rising obesity prevalence, with a rate of 6–9% in recent decades. The mounting prevalence of obesity in emerging countries due to urbanization, sedentary lifestyles, and dietary changes has increased the demand for anti-obesity drugs. A large segment of the population remains undiagnosed or untreated, offering an underpenetrated market for pharmaceutical companies to introduce new therapies and expand their reach. Eli Lilly is preparing to launch its weight-loss and diabetes drug, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), in India, Brazil, and Mexico by 2026.
Brazil is enhancing healthcare infrastructure and obesity management programs, fostering a supportive environment for the introduction and reimbursement of new anti-obesity medications. In April 2024, Brazil opened a laboratory in Hortolândia, São Paulo State, dedicated to producing medications for diabetes and obesity, including liraglutide, an active ingredient found in Ozempic. The EMS-operated plant will also produce semaglutide, a key ingredient in Ozempic, which has a patent valid until March 2026 and is already under review by Agência Nacional de Vigilância Sanitária (ANVISA). With an investment of R$60 million (~US$ 10.93 million), this facility is the first of its kind in Brazil and supports the federal government's Health Economic-Industrial Complex initiatives.
According to the World Economic Forum, initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments. Still, future insurance coverage and generic versions in middle-income countries could improve the accessibility of these medications. Thus, the rising obesity rates, supportive government initiatives, and product innovations are expected to create future growth opportunities for the market in emerging countries.
Anti-obesity Drugs Market Report Segmentation Analysis
Key segments that contributed to the derivation of the anti-obesity drugs market analysis are type, drug class, route of administration, application, and distribution channel.
- Based on type, the anti-obesity drugs market is bifurcated into prescription and OTC. The prescription segment held a larger share of the market in 2024.
- By drug class, the anti-obesity drugs market is segmented into GLP-1 agonists, lipase inhibitors, MC4R agonists, and others. The GLP-1 Agonist segment held the largest share of the market in 2024. GLP-1 agonists segment further subsegmented into Semaglutide, Liraglutide, Tirzepatide.
- Based on application, the anti-obesity drugs market is categorized into appetite suppression, inhibition of fat absorption/digestive enzymes, metabolic enhancement, and combination. The appetite suppression segment held a largest share of the market in 2024.
- In terms of route of administration, the anti-obesity drugs market is bifurcated into oral and parenteral. The oral segment dominated the market in 2024.
- Per distribution channel, the anti-obesity drugs market is categorized into hospital pharmacies, online channel, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.
Anti-obesity Drugs Market Share Analysis by Geography
The geographic scope of the anti-obesity drugs market report mainly focuses on five regions: North America, Asia Pacific, Europe, South & Central America, and the Middle East & Africa. In terms of revenue, North America dominated the global market in 2024 and is expected to continue its dominance during the forecast period. The US is the largest market for anti-obesity drugs in the world. According to the data from the National Health and Nutrition Examination Survey, the prevalence of obesity in adults was 40.3% in the country from August 2021–August 2023. Obesity occurrence was higher in adults aged 40–59 (46.4%) than in people aged 20–39 (35.5%) and 60 and older (38.9%). This surge in obesity rates has led to an increase in related comorbidities such as type 2 diabetes, hypertension, and cardiovascular diseases, escalating healthcare costs. Thus, the demand for effective anti-obesity medications to mitigate these health risks is rising.
Key pharmaceutical companies have introduced innovative treatments that have reshaped the market landscape. Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, have become widely prescribed for type 2 diabetes and obesity management, respectively. Per the Drug Usage Statistics, United States, 2013 – 2022, provided by the ClinCalc DrugStats Database, semaglutide was the 48th most commonly prescribed medication in the US in 2022, with more than 13 million prescriptions. These medications aid in weight reduction and improve the management of obesity-related comorbidities, thereby enhancing their appeal among healthcare providers and patients. Eli Lilly has also made strides with its GLP-1 receptor agonist, tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss. In 2024, Eli Lilly's stock soared 16% following promising results from a Phase 3 trial of its new oral weight-loss drug, orforglipron, which demonstrated an average weight loss of 16 pounds over 40 weeks.
Anti-obesity Drugs Market Report Scope
Anti-obesity Drugs Market News and Recent Developments
The anti-obesity drugs market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. Below are key developments witnessed in the anti-obesity drugs market:
- Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's ) "triple-G" weight-loss drug candidate in a deal worth up to $2 billion. (Source: Novo Nordisk, March 2025)
- AbbVie and Gubra A/S, a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. (Source: AbbVie., Press Release, March 2025)
Anti-obesity Drugs Market Report Coverage and Deliverables
The "Anti-obesity Drugs Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- Anti-obesity drugs market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Anti-obesity drugs market trends, as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Anti-obesity drugs market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the anti-obesity drugs market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market value is expected to reach US$ 177.27 billion by 2031.
The market is expected to register a CAGR of 35.3% during 2025–2031.
Novo Nordisk AS, Eli Lilly and Co, GSK Plc, Rhythm Pharmaceuticals Inc, Currax Pharmaceuticals LLC., VIVUS LLC, AdvaCare Pharma USA LL, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd are key players operating in the market.
Precision medicine and personalized anti-obesity drug regimens are likely to emerge as a new growth trend in the market in the coming years.
The mounting prevalence of obesity and increased awareness and demand for weight management solutions fuel the market growth.
North America dominated the market in 2024.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Analyst Market Outlook
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
3.3 Assumptions and Limitations
4. Anti-Obesity Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Anti-Obesity Drugs Market – Key Market Dynamics
5.1 Anti-Obesity Drugs Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Mounting Prevalence of Obesity
5.2.2 Increased Awareness and Demand for Weight Management Solutions
5.3 Market Restraints
5.3.1 Side Effects and Safety Concerns
5.4 Market Opportunities
5.4.1 Expansion in Emerging Economies
5.5 Future Trends
5.5.1 Precision Medicine and Personalized Anti-Obesity Drug Regimens
5.6 Impact of Drivers and Restraints:
6. Anti-Obesity Drugs Market – Global Market Analysis
6.1 Anti-Obesity Drugs Market Revenue (US$ Million), 2021–2031
6.2 Anti-Obesity Drugs Market Forecast Analysis
7. Anti-Obesity Drugs Market Analysis – by Type
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8. Anti-Obesity Drugs Market Analysis – by Drug Class
8.1 GLP-1 Agonist
8.1.1 Overview
8.1.2 GLP-1 Agonist: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Lipase Inhibitors
8.2.1 Overview
8.2.2 Lipase Inhibitors: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.3 MC4R agonist
8.3.1 Overview
8.3.2 MC4R agonist: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9. Anti-Obesity Drugs Market Analysis – by Application
9.1 Appetite Suppression
9.1.1 Overview
9.1.2 Appetite Suppression: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Inhibition of Fat Absorption or Digestive Enzymes
9.2.1 Overview
9.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Metabolic Enhancement
9.3.1 Overview
9.3.2 Metabolic Enhancement: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Combination
9.4.1 Overview
9.4.2 Combination: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10. Anti-Obesity Drugs Market Analysis – by Route Of Administration
10.1 Oral
10.1.1 Overview
10.1.2 Oral: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Parenteral
10.2.1 Overview
10.2.2 Parenteral: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11. Anti-Obesity Drugs Market Analysis – by Distribution Channel
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.2 Online Channel
11.2.1 Overview
11.2.2 Online Channel: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
12. Anti-Obesity Drugs Market – Geographical Analysis
12.1 Overview
12.2 North America
12.2.1 North America Anti-Obesity Drugs Market Overview
12.2.2 North America: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
12.2.3 North America: Anti-Obesity Drugs Market Breakdown, by Type
12.2.3.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Type
12.2.4 North America: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.2.4.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Drug Class
12.2.4.1.1 North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.2.5 North America: Anti-Obesity Drugs Market Breakdown, by Application
12.2.5.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Application
12.2.6 North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.2.6.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
12.2.7 North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.2.7.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
12.2.8 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.2.8.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.2.8.2 United States: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.2.8.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Type
12.2.8.2.2 United States: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.2.8.2.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.2.8.2.3 United States: Anti-Obesity Drugs Market Breakdown, by Application
12.2.8.2.4 United States: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.2.8.2.5 United States: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.2.8.3 Canada: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.2.8.3.1 Canada: Anti-Obesity Drugs Market Breakdown, by Type
12.2.8.3.2 Canada: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.2.8.3.2.1 Canada: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.2.8.3.3 Canada: Anti-Obesity Drugs Market Breakdown, by Application
12.2.8.3.4 Canada: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.2.8.3.5 Canada: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.2.8.4 Mexico: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.2.8.4.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Type
12.2.8.4.2 Mexico: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.2.8.4.2.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.2.8.4.3 Mexico: Anti-Obesity Drugs Market Breakdown, by Application
12.2.8.4.4 Mexico: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.2.8.4.5 Mexico: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.3 Europe
12.3.1 Europe Anti-Obesity Drugs Market Overview
12.3.2 Europe: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
12.3.3 Europe: Anti-Obesity Drugs Market Breakdown, by Type
12.3.3.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Type
12.3.4 Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.3.4.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Drug Class
12.3.4.1.1 Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.3.5 Europe: Anti-Obesity Drugs Market Breakdown, by Application
12.3.5.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Application
12.3.6 Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.3.6.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
12.3.7 Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.3.7.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
12.3.8 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.3.8.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.3.8.2 Germany: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.3.8.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Type
12.3.8.2.2 Germany: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.3.8.2.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.3.8.2.3 Germany: Anti-Obesity Drugs Market Breakdown, by Application
12.3.8.2.4 Germany: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.3.8.2.5 Germany: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.3.8.3 United Kingdom: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.3.8.3.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Type
12.3.8.3.2 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.3.8.3.2.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.3.8.3.3 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Application
12.3.8.3.4 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.3.8.3.5 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.3.8.4 France: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.3.8.4.1 France: Anti-Obesity Drugs Market Breakdown, by Type
12.3.8.4.2 France: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.3.8.4.2.1 France: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.3.8.4.3 France: Anti-Obesity Drugs Market Breakdown, by Application
12.3.8.4.4 France: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.3.8.4.5 France: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.3.8.5 Spain: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.3.8.5.1 Spain: Anti-Obesity Drugs Market Breakdown, by Type
12.3.8.5.2 Spain: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.3.8.5.2.1 Spain: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.3.8.5.3 Spain: Anti-Obesity Drugs Market Breakdown, by Application
12.3.8.5.4 Spain: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.3.8.5.5 Spain: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.3.8.6 Italy: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.3.8.6.1 Italy: Anti-Obesity Drugs Market Breakdown, by Type
12.3.8.6.2 Italy: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.3.8.6.2.1 Italy: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.3.8.6.3 Italy: Anti-Obesity Drugs Market Breakdown, by Application
12.3.8.6.4 Italy: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.3.8.6.5 Italy: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.3.8.7 Rest of Europe: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.3.8.7.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Type
12.3.8.7.2 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.3.8.7.2.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.3.8.7.3 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Application
12.3.8.7.4 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.3.8.7.5 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.4 Asia Pacific
12.4.1 Asia Pacific Anti-Obesity Drugs Market Overview
12.4.2 Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
12.4.3 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type
12.4.3.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Type
12.4.4 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.4.4.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Drug Class
12.4.4.1.1 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.4.5 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application
12.4.5.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Application
12.4.6 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.4.6.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
12.4.7 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.4.7.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
12.4.8 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.4.8.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.4.8.2 China: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.4.8.2.1 China: Anti-Obesity Drugs Market Breakdown, by Type
12.4.8.2.2 China: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.4.8.2.2.1 China: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.4.8.2.3 China: Anti-Obesity Drugs Market Breakdown, by Application
12.4.8.2.4 China: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.4.8.2.5 China: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.4.8.3 Japan: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.4.8.3.1 Japan: Anti-Obesity Drugs Market Breakdown, by Type
12.4.8.3.2 Japan: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.4.8.3.2.1 Japan: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.4.8.3.3 Japan: Anti-Obesity Drugs Market Breakdown, by Application
12.4.8.3.4 Japan: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.4.8.3.5 Japan: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.4.8.4 India: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.4.8.4.1 India: Anti-Obesity Drugs Market Breakdown, by Type
12.4.8.4.2 India: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.4.8.4.2.1 India: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.4.8.4.3 India: Anti-Obesity Drugs Market Breakdown, by Application
12.4.8.4.4 India: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.4.8.4.5 India: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.4.8.5 Australia: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.4.8.5.1 Australia: Anti-Obesity Drugs Market Breakdown, by Type
12.4.8.5.2 Australia: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.4.8.5.2.1 Australia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.4.8.5.3 Australia: Anti-Obesity Drugs Market Breakdown, by Application
12.4.8.5.4 Australia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.4.8.5.5 Australia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.4.8.6 South Korea: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.4.8.6.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Type
12.4.8.6.2 South Korea: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.4.8.6.2.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.4.8.6.3 South Korea: Anti-Obesity Drugs Market Breakdown, by Application
12.4.8.6.4 South Korea: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.4.8.6.5 South Korea: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.4.8.7 Rest of APAC: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.4.8.7.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Type
12.4.8.7.2 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.4.8.7.2.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.4.8.7.3 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Application
12.4.8.7.4 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.4.8.7.5 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.5 Middle East and Africa
12.5.1 Middle East and Africa Anti-Obesity Drugs Market Overview
12.5.2 Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
12.5.3 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
12.5.3.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Type
12.5.4 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.5.4.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Drug Class
12.5.4.1.1 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.5.5 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
12.5.5.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Application
12.5.6 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.5.6.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
12.5.7 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.5.7.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
12.5.8 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.5.8.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.5.8.2 Saudi Arabia: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.5.8.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Type
12.5.8.2.2 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.5.8.2.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.5.8.2.3 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Application
12.5.8.2.4 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.5.8.2.5 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.5.8.3 South Africa: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.5.8.3.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Type
12.5.8.3.2 South Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.5.8.3.2.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.5.8.3.3 South Africa: Anti-Obesity Drugs Market Breakdown, by Application
12.5.8.3.4 South Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.5.8.3.5 South Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.5.8.4 United Arab Emirates: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.5.8.4.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Type
12.5.8.4.2 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.5.8.4.2.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.5.8.4.3 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Application
12.5.8.4.4 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.5.8.4.5 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.5.8.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.5.8.5.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
12.5.8.5.2 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.5.8.5.2.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.5.8.5.3 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
12.5.8.5.4 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.5.8.5.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.6 South and Central America
12.6.1 South and Central America Anti-Obesity Drugs Market Overview
12.6.2 South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
12.6.3 South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
12.6.3.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Type
12.6.4 South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.6.4.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Drug Class
12.6.4.1.1 South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.6.5 South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
12.6.5.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Application
12.6.6 South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.6.6.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
12.6.7 South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.6.7.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
12.6.8 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.6.8.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country
12.6.8.2 Brazil: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.6.8.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Type
12.6.8.2.2 Brazil: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.6.8.2.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.6.8.2.3 Brazil: Anti-Obesity Drugs Market Breakdown, by Application
12.6.8.2.4 Brazil: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.6.8.2.5 Brazil: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.6.8.3 Argentina: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.6.8.3.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Type
12.6.8.3.2 Argentina: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.6.8.3.2.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.6.8.3.3 Argentina: Anti-Obesity Drugs Market Breakdown, by Application
12.6.8.3.4 Argentina: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.6.8.3.5 Argentina: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
12.6.8.4 Rest of South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
12.6.8.4.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
12.6.8.4.2 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
12.6.8.4.2.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
12.6.8.4.3 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
12.6.8.4.4 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
12.6.8.4.5 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 New Product Development/Approval
13.3 Other Business Strategies
14. Company Profiles
14.1 Novo Nordisk AS
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.2 Eli Lilly and Co
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 GSK Plc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.4 Rhythm Pharmaceuticals Inc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Currax Pharmaceuticals LLC.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 VIVUS LLC
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AdvaCare Pharma USA LLC
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.8 Teva Pharmaceutical Industries Ltd
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.9 Sun Pharmaceutical Industries Ltd
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 F. Hoffmann-La Roche Ltd
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
List of Tables
Table 1. Anti-Obesity Drugs Market Segmentation
Table 2. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million)
Table 3. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million)
Table 4. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 5. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 6. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 7. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 8. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 9. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 10. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 11. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 12. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 13. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 14. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 15. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 16. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 17. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 18. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 19. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 20. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 21. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 22. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 23. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 24. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 25. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 26. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 27. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 28. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Country
Table 29. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Country
Table 30. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 31. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 32. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 33. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 34. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 35. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 36. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 37. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 38. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 39. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 40. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 41. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 42. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 43. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 44. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 45. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 46. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 47. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 48. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 49. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 50. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 51. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 52. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 53. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 54. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 55. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 56. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 57. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 58. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 59. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 60. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 61. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 62. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 63. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 64. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 65. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 66. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 67. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 68. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 69. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 70. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 71. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 72. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 73. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 74. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 75. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 76. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 77. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 78. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Country
Table 79. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Country
Table 80. ADULT OBESITY IN 2030
Table 81. CHILD OBESITY IN 2030
Table 82. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 83. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 84. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 85. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 86. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 87. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 88. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 89. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 90. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 91. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 92. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 93. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 94. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 95. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 96. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 97. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 98. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 99. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 100. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 101. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 102. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 103. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 104. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 105. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 106. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 107. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 108. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 109. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 110. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 111. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 112. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 113. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 114. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 115. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 116. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 117. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 118. ADULT OBESITY IN 2030
Table 119. CHILD OBESITY IN 2030
Table 120. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 121. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 122. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 123. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 124. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 125. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 126. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 127. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 128. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 129. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 130. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 131. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 132. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 133. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 134. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 135. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 136. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 137. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 138. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 139. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 140. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 141. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 142. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 143. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 144. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 145. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 146. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 147. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 148. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 149. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 150. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 151. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 152. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 153. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 154. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 155. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 156. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 157. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 158. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 159. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 160. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 161. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 162. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 163. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 164. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 165. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 166. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 167. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 168. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Country
Table 169. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Country
Table 170. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 171. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 172. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 173. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 174. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 175. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 176. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 177. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 178. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 179. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 180. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 181. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 182. ADULT OBESITY IN 2030
Table 183. CHILD OBESITY IN 2030
Table 184. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 185. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 186. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 187. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 188. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 189. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 190. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 191. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 192. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 193. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 194. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 195. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 196. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 197. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 198. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 199. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 200. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 201. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 202. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 203. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 204. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 205. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 206. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 207. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 208. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 209. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 210. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 211. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 212. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 213. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 214. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 215. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 216. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 217. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 218. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 219. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 220. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 221. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 222. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 223. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 224. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 225. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 226. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 227. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 228. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 229. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 230. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 231. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 232. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 233. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 234. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 235. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 236. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 237. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 238. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 239. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 240. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 241. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 242. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 243. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 244. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 245. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 246. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 247. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 248. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 249. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 250. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 251. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 252. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 253. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 254. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 255. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 256. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Country
Table 257. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Country
Table 258. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 259. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 260. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 261. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 262. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 263. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 264. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 265. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 266. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 267. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 268. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 269. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 270. ADULT OBESITY IN 2030
Table 271. CHILD OBESITY IN 2030
Table 272. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 273. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 274. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 275. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 276. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 277. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 278. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 279. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 280. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 281. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 282. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 283. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 284. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 285. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 286. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 287. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 288. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 289. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 290. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 291. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 292. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 293. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 294. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 295. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 296. ADULT OBESITY IN 2030
Table 297. CHILD OBESITY IN 2030
Table 298. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 299. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 300. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 301. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 302. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 303. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 304. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 305. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 306. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 307. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 308. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 309. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 310. South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 311. South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 312. South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 313. South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 314. South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 315. South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 316. South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 317. South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 318. South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 319. South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 320. South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 321. South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 322. South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Country
Table 323. South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Country
Table 324. Brazil: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 325. Brazil: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 326. Brazil: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 327. Brazil: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 328. Brazil: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 329. Brazil: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 330. Brazil: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 331. Brazil: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 332. Brazil: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 333. Brazil: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 334. Brazil: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 335. Brazil: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 336. ADULT OBESITY IN 2030
Table 337. CHILD OBESITY IN 2030
Table 338. Argentina: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 339. Argentina: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 340. Argentina: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 341. Argentina: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 342. Argentina: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 343. Argentina: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 344. Argentina: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 345. Argentina: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 346. Argentina: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 347. Argentina: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 348. Argentina: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 349. Argentina: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 350. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Type
Table 351. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Type
Table 352. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Drug Class
Table 353. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Drug Class
Table 354. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Glp-1 Agonist
Table 355. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Glp-1 Agonist
Table 356. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Application
Table 357. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Application
Table 358. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Route Of Administration
Table 359. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route Of Administration
Table 360. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 361. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 362. Glossary of Terms, Anti-obesity Drugs Market
List of Figures
Figure 1. Anti-Obesity Drugs Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Anti-Obesity Drugs Market Revenue (US$ Million), 2021–2031
Figure 5. Anti-Obesity Drugs Market Share (%) – by Type (2024 and 2031)
Figure 6. Prescription Drugs: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. OTC Drugs: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Anti-Obesity Drugs Market Share (%) – by Drug Class (2024 and 2031)
Figure 9. GLP-1 Agonist: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Lipase Inhibitors: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. MC4R agonist: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Others: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Anti-Obesity Drugs Market Share (%) – by Application (2024 and 2031)
Figure 14. Appetite Suppression: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Metabolic Enhancement: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. Combination: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Anti-Obesity Drugs Market Share (%) – by Route Of Administration (2024 and 2031)
Figure 19. Oral: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Parenteral: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Anti-Obesity Drugs Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 22. Hospital Pharmacies: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Online Channel: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. Retail Pharmacies: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. Anti-Obesity Drugs Market Breakdown by Region, 2024 and 2031 (%)
Figure 26. North America: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 27. North America: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
Figure 28. North America: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
Figure 29. North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
Figure 30. North America: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
Figure 31. North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
Figure 32. North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
Figure 33. North America: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 34. United States: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 35. Canada: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 36. Mexico: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 37. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 38. Europe: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
Figure 39. Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
Figure 40. Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
Figure 41. Europe: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
Figure 42. Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
Figure 43. Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
Figure 44. Europe: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 45. Germany: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 46. United Kingdom: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 47. France: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 48. Spain: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 49. Italy: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 50. Rest of Europe: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 51. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 52. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
Figure 53. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
Figure 54. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
Figure 55. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
Figure 56. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
Figure 57. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
Figure 58. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 59. China: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 60. Japan: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 61. India: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 62. Australia: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 63. South Korea: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 64. Rest of APAC: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 65. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 66. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
Figure 67. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
Figure 68. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
Figure 69. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
Figure 70. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
Figure 71. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
Figure 72. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 73. Saudi Arabia: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 74. South Africa: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 75. United Arab Emirates: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 76. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 77. South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US$ Million)
Figure 78. South and Central America: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
Figure 79. South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
Figure 80. South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
Figure 81. South and Central America: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
Figure 82. South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
Figure 83. South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
Figure 84. South and Central America: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 85. Brazil: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 86. Argentina: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 87. Rest of South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
The List of Companies - Anti-obesity Drugs Market
- Novo Nordisk AS
- Eli Lilly and Co
- GSK Plc
- Rhythm Pharmaceuticals Inc
- Currax Pharmaceuticals LLC.
- VIVUS LLC
- AdvaCare Pharma USA LL
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- F. Hoffmann-La Roche Ltd
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For